Myriad Genetics (MYGN) Change in Receivables (2009 - 2026)

Myriad Genetics (MYGN) has reported Change in Receivables for 18 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables rose 1187.5% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $3.3 million (down 17.5% YoY), while the FY2025 annual figure was -$6.2 million, down 171.26% from the prior year.
• Change in Receivables climbed to $8.7 million in Q1 2026 per MYGN's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $17.5 million in Q1 2023 and bottomed at -$19.0 million in Q3 2025.
• Historically, Change in Receivables has averaged $2.0 million across 5 years, with a median of $600000.0 in 2024.
• Annual changes were most pronounced in 2022 — Change in Receivables slumped 1120.0% — and 2025, when it jumped 2600.0%.
• Myriad Genetics' Change in Receivables stood at -$2.5 million in 2022, then surged by 52.0% to -$1.2 million in 2023, then slumped by 233.33% to -$4.0 million in 2024, then jumped by 35.0% to -$2.6 million in 2025, then soared by 434.62% to $8.7 million in 2026.
• Business Quant data shows MYGN's Change in Receivables at $8.7 million in Q1 2026, -$2.6 million in Q4 2025, and -$19.0 million in Q3 2025.